Dyadic International, Inc. Appoints Arindam Bose, Ph.D., Distinguished Life Sciences Executive, to Board of Directors
August 16 2016 - 11:12AM
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global
biotechnology company focused on the development and large scale
manufacture of low cost, better performing biologic vaccines and
drugs at flexible commercial scales, today announced the
appointment of Arindam Bose, Ph.D., to its Board of Directors,
effective August 15, 2016.
Dr. Bose recently retired from Pfizer Research
& Development after serving for 34 years, most recently in
senior leadership roles in process development and manufacturing of
biologics. Specifically, for the last six years, Dr. Bose
served as Vice President of Bio Therapeutics Pharmaceutical
Sciences External Affairs and Biosimilars Strategy. In that role,
Dr. Bose led the technical team which was responsible for
researching, developing and executing Pfizer’s strategy for entry
into the emerging field of biosimilars. That effort resulted in the
successful submission of 5 Investigational New Drug Applications
(INDs) to the FDA: all 5 of which have already progressed to Phase
3 testing. Dr. Bose was also a member of Pfizer’s Bioprocess
Leadership Team (BPLT) – Pfizer’s most senior oversight team for
biotechnology product technical development and manufacturing.
“We are very excited that Dr. Bose has joined
Dyadic’s board of directors,” said Mark Emalfarb, Dyadic’s CEO.
“His extensive background in biologics products, process
development and commercial experiences make him an ideal scientific
and business advisor to provide guidance and insight to Dyadic’s
biologics business strategy and research initiatives.” Mr.
Emalfarb continued, “Dr. Bose has an extensive global network of
key business and research relationships that we expect will help us
accelerate the introduction and adoption of our C1 technology in
the biotech and pharmaceutical industry for use in the development
and manufacture of biologic vaccines and drugs.”
Dr. Bose commented, "I am truly excited to join
the Dyadic Board of Directors. I view the C1 technology platform as
a leap in technology that has the potential to change the way in
which both animal health and human biotech and pharmaceutical
companies bring their biologic vaccines and drugs to market faster,
in greater volumes, at lower cost, and with newer beneficial
properties.”
Prior positions held by Dr. Bose at Pfizer
included: Executive Director, Human Biologics Strategy &
Sourcing (2003-2009), Director, Human Biologicals (2000-2003),
Senior Technical Advisor, Human Biologicals (1997-2000), and
Manager, Bioprocess Development (1991-1997).
Dr. Bose began his career as a research
scientist at the Battelle Memorial Institute where he worked on
biochemical process technology. He received a Ph.D. in
chemical engineering from Purdue University and a M.S. in chemical
engineering from the University of Michigan, Ann Arbor. Dr.
Bose was elected a Fellow of the American Chemical Society,
American Institute of Chemical Engineers and American Institute for
Medical and Biological Engineering in recognition of his
outstanding professional accomplishments.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant protein production system based on the
fungus Myceliopthora thermophila, nicknamed C1. The C1
microorganism, which enables the development and large scale
manufacture of low cost proteins, has the potential to be further
developed into a safe and efficient expression system that may help
speed up the development, production and performance of biologic
drugs at flexible commercial scales. Dyadic is using the C1
technology and other technologies to conduct research, development
and commercial activities for the development and manufacturing of
human and animal vaccines, monoclonal antibodies, biosimilars
and/or biobetters, and other therapeutic proteins. Dyadic pursues
research and development collaborations, licensing arrangements and
other commercial opportunities with its partners and collaborators
to leverage the value and benefits of these technologies in
developing and manufacturing biopharmaceuticals which these
technologies help produce. In particular, as the aging population
grows in developed and undeveloped countries, Dyadic believes the
C1 technology may help bring biologic drugs to market faster, in
greater volumes, at lower cost, and with new properties to drug
developers and manufacturers and, hopefully, improve access and
cost to patients and the healthcare system, but most importantly
saving lives. Please visit Dyadic’s website at www.dyadic.com for
additional information, including details regarding Dyadic’s plans
for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic, as well as additional
information related to its professional liability lawsuit, in the
company’s annual and quarterly reports which are filed with the OTC
markets. Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
Certain statements contained in this press
release are forward-looking statements within the meaning of the
federal securities laws. These forward-looking statements involve
risks, uncertainties and other factors that could cause Dyadic’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Investors
are urged to consider these factors carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such forward-looking statements. Any forward-looking
statements speak only as of the date of this press release and,
except as required by law, Dyadic expressly disclaims any intent or
obligation to update or revise any forward-looking statements to
reflect actual results, any changes in expectations or any change
in events. Factors that could cause results to differ materially
include, but are not limited to: (1) general economic, political
and market conditions (2) our ability to carry out and implement
our biopharmaceutical research and business plans and strategic
initiatives (3) Dyadic’s ability to retain and attract employees,
consultants, directors, advisors and contract research
organizations (4) our ability to implement and successfully carry
out Dyadic’s and third parties research and development efforts (5)
our ability to obtain new license and research agreements (6)
competitive pressures and reliance on key customers and
collaborators (7) the outcome of the current litigation by Dyadic
against its former counsel and (8) other factors discussed in
Dyadic’s publicly available filings, including information set
forth under the caption “Risk Factors” in our December 31, 2015
Annual Report filed with OTC Markets on March 29, 2016. New risks
and uncertainties arise from time to time, and it is impossible for
us to predict these events or how they may affect us.
Contact:
Dyadic International, Inc.
Thomas L. Dubinski
Chief Financial Officer
Phone: 561-743-8333
Email: tdubinski@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024